118 related articles for article (PubMed ID: 3882442)
1. Comparison of three techniques for the ex vivo elimination of T cells from human bone marrow.
Blazar BR; Quinones RR; Heinitz KJ; Sevenich EA; Filipovich AH
Exp Hematol; 1985 Feb; 13(2):123-8. PubMed ID: 3882442
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two immuno-mechanical methods of T-cell depletion of human bone-marrow for prevention of graft-versus-host disease: soybean lectin agglutination and sheep erythrocyte rosette depletion versus triple rosette depletion.
Woolfrey AE; Neudorf S; Filipovich AH
Thymus; 1985; 7(6):327-34. PubMed ID: 3909540
[TBL] [Abstract][Full Text] [Related]
3. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
[TBL] [Abstract][Full Text] [Related]
4. T cell depletion from human bone marrow using magnetic beads.
Knobloch C; Spadinger U; Rueber E; Friedrich W
Bone Marrow Transplant; 1990 Jul; 6(1):21-4. PubMed ID: 2390629
[TBL] [Abstract][Full Text] [Related]
5. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies].
Hervé P; Flesch M
Nouv Rev Fr Hematol (1978); 1986; 28(2):97-105. PubMed ID: 2942838
[TBL] [Abstract][Full Text] [Related]
6. T-cell depletion and allogeneic bone marrow transplantation.
O'Reilly RJ
Semin Hematol; 1992 Apr; 29(2 Suppl 1):20-6. PubMed ID: 1615341
[No Abstract] [Full Text] [Related]
7. [Ex-vivo treatment of a bone marrow graft].
Bieva CJ
Rev Med Brux; 1992 May; 13(5):177-82. PubMed ID: 1609193
[TBL] [Abstract][Full Text] [Related]
8. T-cell depletion of bone marrow transplants: assessment of standard immunological methods of quantification.
Autran B; Beaujean F; Pillier C; Kuentz M; Leblond V; Debré P; Bernard A; Binet JL; Duedari N; Vernant JP
Exp Hematol; 1987 Dec; 15(11):1121-7. PubMed ID: 3315722
[TBL] [Abstract][Full Text] [Related]
9. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
[TBL] [Abstract][Full Text] [Related]
10. Optimal conditions for in vitro T cell depletion of human bone marrow by Campath-1a plus complement as demonstrated by limiting dilution analysis.
Frame JN; Sheehy D; Cartagena T; Cirrincione C; O'Reilly RJ; Dupont B; Kernan NA
Bone Marrow Transplant; 1989 Jan; 4(1):55-61. PubMed ID: 2784335
[TBL] [Abstract][Full Text] [Related]
11. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
12. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
Soderling CC; Song CW; Blazar BR; Vallera DA
J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
[TBL] [Abstract][Full Text] [Related]
13. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
14. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique.
Meijer E; Slaper-Cortenbach IC; Thijsen SF; Dekker AW; Verdonck LF
Bone Marrow Transplant; 2002 Feb; 29(4):335-9. PubMed ID: 11896431
[TBL] [Abstract][Full Text] [Related]
15. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
Blazar BR; Taylor PA; Vallera DA
J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
[TBL] [Abstract][Full Text] [Related]
16. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
18. Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation.
Ramakrishnan S; Uckun FM; Houston LL
J Immunol; 1985 Nov; 135(5):3616-22. PubMed ID: 3900212
[TBL] [Abstract][Full Text] [Related]
19. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo depletion of human bone marrow T lymphocytes by soybean lectin fractionation followed by treatment with an anti-pan-T cell (CD5) ricin A- chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplant Proc; 1987 Feb; 19(1 Pt 3):2735-7. PubMed ID: 3274583
[No Abstract] [Full Text] [Related]
[Next] [New Search]
